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Abstract
Background: Coccidioidomycosis or Valley Fever is caused by Coccidioides in Southwest US and
Central America. Primary pulmonary infection is initiated by inhalation of air-borne arthroconidia.
Since, lung is the first organ that encounters arthroconidia, different components of the pulmonary
innate immune system may be involved in the regulation of host defense. Pulmonary surfactant
proteins (SP)-A and SP-D have been recognized to play an important role in binding and
phagocytosis of various microorganisms, but their roles in Coccidioides infection are not known.
Methods:  In this study, we studied the changes in amounts of pulmonary SP-A, SP-D and
phospholipid in murine model of Coccidioides posadasii infection, and binding of SP-A and SP-D to
Coccidioidal antigens. Mice were challenged intranasally with a lethal dose of C. posadasii (n = 30
arthroconidia) and bronchoalveolar lavage fluid (BALF) samples were collected on day 10, post
infection. In another group of animals, mice were immunized with protective formalin killed
spherule (FKS) vaccine prior to infection. The concentrations of BALF SP-A, SP-D, total
phospholipid were measured using enzyme linked immunosorbent assay and biochemical assays.
Results: We found that in lavage fluid samples of C. posadasii infected mice, the concentrations of
total phospholipid, SP-A and SP-D were 17 % (SEM 3.5, p < 0.001), 38 % (SEM 5.8, p < 0.001) and
4 % (SEM 1.3, p < 0.001) of those in lavage fluid samples of non-infected control mice, respectively.
However, the concentrations of SP-A and SP-D remained unchanged in BALF samples of C.
posadasii protected mice after immunization with FKS vaccine. Also, we found that both SP-A and
SP-D bind to Coccidiodal antigens.
Conclusion: Our results suggest that the C. posadasii infection perturbs the pulmonary SP-A, SP-
D, and phospholipids, potentially enabling the disease progression and promoting fungal
dissemination.
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Background
Coccidioidomycosis or Valley Fever is a fungal disease
caused by the biphasic, highly virulent, soil-fungus Coccid-
ioides immitis or posadasii [1]. It is endemic in the south-
west regions of US, Northern Mexico and parts of Central
America [2]. C. posadasii or C. immitis, are the most viru-
lent fungal pathogens enlisted in Select Agent list and
pose a risk for bioterrorism [3]. The primary infection is
acquired by inhalation of air-borne, mycelial phase
arthroconidium that converts into endosporulating
spherule in the lung. Clinical manifestations of the dis-
ease range from pulmonary infection to a more severe
fatal mycosis involving extra-pulmonary tissues in 1–10%
of the infected people [1-4]. Previous studies suggest that
Th1 cell mediated immunity protects individuals against
Coccidioides [5,6]. However, information is lacking regard-
ing the pulmonary innate immune components that may
play a critical role in regulation of immune responses
against Coccidioides.
At alveolar level in the lung, the innate immune system is
composed of many cell types and chemical mediators,
including surfactant. The pulmonary surfactant is a com-
plex mixture of lipids (88–90%) and proteins (10–12%),
synthesized by type II epithelial cells and Clara cells. It
lines the alveoli, and helps in maintaining normal lung
function [7]. Among four different surfactant proteins,
surfactant proteins-A (SP-A) and D (SP-D) are members of
the "Collectin" family [8]. In the past, several studies have
suggested that both SP-A and SP-D play an important role
in innate host defense against various viral, fungal and
bacterial pathogens [9,10]. More evidence for the pulmo-
nary collectins' role in host defense comes from studies on
SP-A- deficient mice that are susceptible to intra-tracheal
Group B Streptococci  [11],  Pseudomonas aeruginosa [12],
and Respiratory Syncytial Virus [13]. Also, intranasally
administered SP-D has been found to reduce replication
of Respiratory Syncytial Virus in the lungs of infected mice
[14]. Both SP-A and SP-D, have been classified as secretory
pattern-recognition receptors that can bind to a variety of
pathogens and help in clearance [9,15]. Recent evidences
indicate that in addition to their pathogen recognition
property, SP-A and SP-D also play an important role in
stimulating immuno-regulatory pathways [15]. However,
the collectins' role in coccidioidomycosis is not known.
This study focuses on analyzing the changes in amounts of
the SP-A and SP-D in the bronchoalveolar lavage fluid
(BALF) samples from mice infected with lethal dose of C.
posadasii and C. posadasii protected mice after immuniza-
tion with protective formalin killed spherule (FKS) vac-
cine, and binding of pulmonary collectins to Coccidioidal
antigens.
Methods
Mice
BALB/c and C57BL6 mice (6 weeks old female) from Jack-
son Laboratory (Bar Harbour, ME) were used in this study.
Both mouse strains are susceptible to C. posadasii infec-
tion. The BALB/c mice were used to study the changes in
pulmonary surfactant after intranasal challenge with C.
posadasii. And, the C57BL6 mice were used to study the
changes in pulmonary surfactant after vaccination with
protective FKS vaccine. Mice were housed in Biosafety
Level-3 animal facility at UTHSCSA and provided with
food and water ad libitum. All experimental animal care
and treatment protocols were reviewed and approved by
Institutional Animal Care and Use Committee.
Coccidioides posadasii
C. immitis (now posadasii) Silveira strain, cultured on 1 %
glucose-0.5 % yeast extract agar (GYE), was used for
infecting the mice [1]. The arthroconidia were harvested
in endotoxin-free 0.15 M saline (Baxter Health Care Prod-
ucts, Deerfield, IL) from 6–8 weeks old mycelial phase
cultures grown on GYE plates. The arthroconidia suspen-
sion was passed over a sterile cotton column to remove
hyphal elements and arthroconidia were enumerated by
hemacytometer counts. The viable cfu counts were con-
firmed pre- and post-infection by plate cultures on GYE
agar. All the experiments with C. posadasii were carried out
in Biosafety Level-3 facility at UTHSCSA.
Intranasal Challenge with C. posadasii Arthroconidia
Mice were anaesthetized after intramuscular injection of
ketamine- xylazine (75 µg/g body weight ketamine and 10
µg/g body weight xylazine) and were then challenged
intranasally with a lethal dose of arthroconidia (n = 30,
fresh harvest of C. posadasii arthroconidia) suspended in
endotoxin-free 0.15 M NaCl (Baxter Health Care Corp,
Deerfield, IL) using sterile pyrogen-free microtip. Mice
were held in an upright position for 1–2 min to resume
normal breathing after injection. Control mice were chal-
lenged with equal volume of endotoxin-free 0.15 M NaCl.
Preparation of Coccidioide-FKS vaccine and 
Immunization of Mice
C. posadasii (strain Silveira)arthroconidia were used to pre-
pare FKS as described earlier [16]. Briefly, arthroconidia
were inoculated in modified Converse medium contain-
ing Tamol and cultured while shaking at 180 rpm at 40°C
in 20 % CO2 incubator. The spherules were collected from
the harvested culture, washed in endotoxin-free water and
killed with 1 % formalin. FKS preparation was checked for
sterility and lyophilized. C57BL6 female mice (age 6
weeks old) were immunized intramuscularly twice and
subcutaneously once at one week interval with FKS (0.7
mg/dose each time). The mice in FKS immunized,
infected group were then challenged intranasally with 30Respiratory Research 2004, 5:28 http://respiratory-research.com/content/5/1/28
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C. posadasii arthroconidia, 15 days after last immuniza-
tion, as described above.
Fungal Burden Assay
Mice were anaesthetized as mentioned above, prior to sac-
rifice on day 10, post intranasal infection. This standard
procedure was used for intranasal injection since it does
not cause respiratory depression during anaesthesia. The
lung and spleen tissues were collected in sterile 0.15 M
NaCl for studying fungal load.
The fungal burden was studied by plating ten fold dilu-
tions of lung and spleen homogenates in 0.15 M saline on
Mycosel agar plates (BD Biosciences, Franklin Lakes, NJ)
and incubating for 72 h at 30°C. The cfu counts were
recorded and normalized with organ weight.
Collection and Processing of BALF
At the time of necropsy, we collected BALF by injecting 1
ml endotoxin-free 0.15 M NaCl solution (Baxter Health
Care Corp, Deerfield, IL) three times, via an angiocatheter
(BD Biosciences, San Diego, CA) placed in the trachea.
The volume of the input solution was kept constant (3 ml
total) and approximately, 90–95 % of the solution was
recovered consistently. The BALF was centrifuged at 500
rpm for 10 min at 4°C to remove cells. The cell free BALF
supernatant was filtered through 0.2 µm syringe filters
(Nalge Nunc International, Rochester, NY) and stored at -
80°C for further analysis.
Total Protein and Lipid Analysis
The total protein concentration was measured in BALF
specimens using micro bicinchonic acid protein assay kit
(Pierce, Rockford, IL) against bovine serum albumin
(BSA) standard protein. The total phospholipid content in
lipid extracts of BALF specimens was determined using the
method of Stewart, against Dipalmitoyl-phosphatidyl-
choline (DPPC, Avanti Polar Lipids, Alabaster, AL) stand-
ard solutions [17,18]. Briefly, the lipid extract of BALF
specimens and DPPC standard solutions was completely
dried under compressed nitrogen gas. The dried lipids
were dissolved in chloroform and mixed with 1 ml of
2.7% ferric chloride and 3% ammonium thiocyanate in
glass tubes. The mixture was vortex mixed for 1 min and
centrifuged at 200 rpm for 5 min. The bottom red lower
layer of phospholipids and ammonium ferro-thiocyanate
complex was collected and absorbance was read at 488
nm.
Western Blotting
The BALF and lung tissue homogenate samples (total pro-
tein 10–50 µg) were run on 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) running
gel and transferred on nitrocellulose membranes (Sch-
leicher & Schuell, Keene, NH) overnight at 15 mA current.
The nonspecific sites on the membrane with transferred
proteins were blocked by 15% nonfat milk in Tris-buff-
ered saline containing 0.05% tween 20 (TBST). The mem-
brane was washed and incubated for 1 h with diluted
(1:500) primary anti-human SP-A polyclonal antibody
raised in rabbit (obtained from Dr. Richard J. King, UTH-
SCSA, San Antonio, TX) or anti-mouse SP-D antibody
(kindly provided by Dr. Jo Rae Wright, Duke University
Medical Center, Durham, NC). After washing the mem-
brane with TBST, the membrane was incubated for 1 h
with 1:10,000 diluted alkaline phosphatase conjugated
anti-rabbit IgG raised in goat (Sigma Chemical Co, St.
Louis, MO). The immunoreactive bands were observed by
alkaline phosphatase conjugate system (Biorad, Hercules,
CA). Purified human SP-A (kindly provided by Dr. Rich-
ard J. King, UTHSCSA, San Antonio, TX) and recombinant
human SP-D (kindly provided by Dr. Erika C. Crouch,
Washington University in St. Louis, St. Louis, MO) were
run with the samples.
The Coccidioidal antigens: lysates and filtrates of Coccid-
ioidin (CDN), prepared as a toluene-induced lysate of
young C. posadasii mycelia (obtained from Dr. Rebecca A.
Cox, UTHSCSA, San Antonio, TX, [19]) were also run to
check the cross-reactivities of anti-SP-A and SP-D antibod-
ies to fungal antigens.
Western blot for (A) SP-A and (B) SP-D proteins in mouse  lung Figure 1
Western blot for (A) SP-A and (B) SP-D proteins in mouse 
lung. Lanes (a, b): 2.5 µg total lavage fluid protein (c, d): 100 
µg of total lung tissue homogenate protein from two healthy, 
non-infected BALB/c mice, and (e): 10 ng purified human SP-
A or recombinant SP-D protein.Respiratory Research 2004, 5:28 http://respiratory-research.com/content/5/1/28
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Enzyme-Linked Immunosorbent Assay (ELISA) for SP-A 
and SP-D
The concentrations of SP-A and SP-D were measured in
BALF samples as described earlier [20]. The antibodies
against SP-A and SP-D reacted with 34 kDa (SP-A) and 43
kDa (SP-D) immunroreactive bands in BALF and lung tis-
sue homogenates (Fig 1). For measuring the lavage con-
centrations of SP-A and SP-D, the indirect ELISA
procedure was used [20]. Briefly, the wells of Immulon 4
strips (Dynatech, Chantilly, VA) were coated overnight
with purified human SP-A or recombinant human SP-D
antigens (standards) and diluted BALF (three different
dilutions) in 0.1 M NaHCO3, pH 9.6. The wells were
washed three times with deionized water, and nonspecific
sites were blocked with a buffer containing 0.25% BSA,
0.05% tween 20, 0.17 M boric acid and 0.12 M NaCl, pH
8.5. The wells were washed and incubated for 2 h with
rabbit anti-human SP-A or rabbit anti-mouse SP-D anti-
body. After washing the wells, the horseradish peroxidase
conjugated anti-rabbit IgG antibody (Sigma, St. Louis,
MO) was added. After incubation for 2 h, the wells were
washed again and incubated with tetramethylbenzidine
substrate reagent (Sigma Chemical Co. St. Louis, MO).
The reaction was stopped by adding 50 µl of 2 N H2SO4
and read at 450 nm spectrophotometrically. The regres-
sion coefficient for a least-square linear fit to the standard
curve of SP-A and SP-D was 0.99. The limits of detection
for SP-A and SP-D were 2 ng/ml.
Binding of SP-A and SP-D to Coccidioidal Antigens
A microtiter well based method [21] was used to study the
SP-A and SP-D interactions with Coccidioidal antigens
(CDN-lysate and CDN-filtrate). Briefly, microtiter wells
(Immulon 4; Dynatech, Chantilly, VA) were coated with
50 µl of CDN-lysate (10 µg/ml diluted in 0.1 M NaHCO3
buffer, pH 9.6) or CDN-filtrate (10 µg/ml diluted in 0.1 M
NaHCO3 buffer, pH 9.6) or BSA (10 µg/ml diluted in 0.1
M NaHCO3 buffer, pH 9.6) at room temperature. The
nonspecific binding was blocked with phosphate buffered
saline (pH 7.4) containing 0.1% triton-X 100 and 3%
nonfat milk (buffer A). The purified human SP-A and
recombinant human SP-D diluted in 20 mM Tris (pH 7.4)
containing 0.15 M NaCl, 5 mM CaCl2 and 1 mg/ml BSA
were then added to the wells and incubated for 3 h at
37°C. The wells were then washed with buffer A and incu-
bated for 1 h at room temperature with diluted (1:1000 in
buffer A) anti-SP-A and anti-SP-D antibodies. After wash-
ing the wells, the horseradish peroxidase conjugated anti-
rabbit IgG antibody (Sigma, St. Louis, MO) was added.
After incubation for 2 h, the wells were washed again and
incubated with tetramethylbenzidine substrate reagent
(Sigma Chemical Co. St. Louis, MO). The reaction was
stopped by adding 2 N H2SO4  and read at 405 nm
spectrophotometrically.
The coating of Coccidioidal antigens (CDN-lysate and
CDN-filtrate) to the plates was confirmed using a positive
control antibody that recognizes Coccidioidal antigens as
described earlier [22]. The alkaline phosphatase-conju-
gated rat anti-mouse IgG antibody (Zymed, San Francisco,
CA) served as secondary detection antibody.
Statistics
Statistical analyses of the data (t-test or ANOVA) were
done using Prism Software (Graphpad Software, San
Diego, CA). The p value <0.05 was considered significant.
Results
Pathological status
All of the C. posadasii infected mice survived till the day of
sacrifice (day 10 post infection). However, the mice were
lethargic and lost body weight (Table 1). Abscess like
lesions were quite evident on gross examination of the
lung. The total wet lung weights were increased in C. posa-
dasii infected mice.
The mean protein content of BALF samples from infected
mice was 788 µg versus 326 µg protein in BALF samples
from non-infected saline injected control mice, after 10
days of intranasal infection (p < 0.05, Table 2). In
contrast, the phospholipid concentration was reduced in
BALF samples from C. posadasii infected mice (58 µg)
when compared to non-infected saline injected controls
(165 µg, p < 0.05).
Table 1: Body weights (g) of C. posadasii infected and non-infected BALB/c mice (n = 10 of each type). Values are shown as Mean (SEM) 
of one representative experiment of two independent experiments.
Days post challenge → Mice ↓ Day 0 Day 10
Non-infected 18.36 (0.29) 19.46 (0.23) **
C. posadasii infected 17.77 (0.39) 16.35 (0.53) *, #
** p < 0.01 as compared to non-infected control mice at day 0.
*p < 0.05, # p < 0.0001 as compared to C. posadasii infected mice at day 0 and non-infected mice at day 10, respectively (t-test).Respiratory Research 2004, 5:28 http://respiratory-research.com/content/5/1/28
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The amounts of SP-A, SP-D and phospholipid are reduced 
in BALF samples from C. posadasii infected mice
The anti-human-SP-A and anti-mouse SP-D antibodies
recognized 34 kDa and 43 kDa monomer bands of SP-A
and SP-D in BALF and lung tissue samples (Fig 1). The
upper bands of approximately 68 kDa and 85 kDa size
(dimer of SP-A and SP-D protein) were also visible in
lanes e of Figure 1A and 1B due to incomplete reduction,
respectively. There were no differences in the detectable
isoforms of SP-A or SP-D in the BALF samples from
infected mice as compared to non-infected control mice
(data not shown). The antibodies did not cross-react with
Coccidioidal antigens in CDN lysate or CDN filtrate (Fig
2). The amounts of SP-A and SP-D were significantly
reduced in BALF samples from C. posadasii infected BALB/
c mice when compared to saline injected, non-infected
control mice after 10 days of intranasal challenge (p <
0.001) (Fig 3A). No significant changes were observed in
the amounts of SP-A and SP-D in BALF samples collected
from BALB/c mice, 5 days after intranasal challenge with
C. posadasii (data not shown).
The fungal colonies of C. posadasii were recovered from
both lung and spleens of infected animals indicating the
presence of active infection (Fig 4). Recovery of fungus in
the spleen provides evidence of dissemination of C. posa-
dasii to extra-pulmonary organs.
Lavage SP-A and SP-D levels are unaltered in C. posadasii 
protected mice
No significant changes were seen in SP-A or SP-D levels in
BALF samples of protected (FKS immunized, C. posadasii
Table 2: Total protein and phospholipid contents in BALF samples from non-infected and C. posadasii infected BALB/c mice (n = 5 of 
each type). Values are shown as Mean (SEM) from one represenative experiment of two independent experiments.
Mice Total protein (µg) Total phospholipid (µg)
Non-infected 326.0 (26.9) 165.5 (10.8)
C. posadasii infected 788.7 (248.6)* 58.7 (15.7)*
* p < 0.05 as compared to non-infected control mice (t-test).
Western blot of CDN-lysate and CDN-filtrate for crossreac- tivity with (A) anti-human SP-A and (b) anti-mouse SP-D  antibodies Figure 2
Western blot of CDN-lysate and CDN-filtrate for crossreac-
tivity with (A) anti-human SP-A and (b) anti-mouse SP-D anti-
bodies. Lanes (a): 20 µg, (b): 10 µg and (c): 1 µg CDN-filtrate 
protein. Lanes (d): 20 µg, (e): 10 µg and (f): 1 µg CDN-lysate 
protein and last lane: 10 ng purified human SP-A protein or 
recombinant SP-D protein.
SP-A and SP-D levels in BALF samples from (A) C. posadasii  infected BALB/c mice (ng/µg protein, % of non-infected con- trol mice, n = 5 of each type) (B) FKS immunized, C. posadasii  infected C57BL6 mice (protected mice) (ng/µg protein, % of  FKS immunized non-infected mice, n = 5 of each type) Figure 3
SP-A and SP-D levels in BALF samples from (A) C. posadasii 
infected BALB/c mice (ng/µg protein, % of non-infected con-
trol mice, n = 5 of each type) (B) FKS immunized, C. posadasii 
infected C57BL6 mice (protected mice) (ng/µg protein, % of 
FKS immunized non-infected mice, n = 5 of each type). The 
data are shown from one representative experiment of two 
independent experiments. * p < 0.001 (ANOVA)Respiratory Research 2004, 5:28 http://respiratory-research.com/content/5/1/28
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arthroconidia infected) C57BL6 mice when compared to
FKS immunized, non-infected mice (Fig 3B). Also, there
was no significant change in total protein content in BALF
samples of FKS immunized, C. posadasii arthroconidia
infected mice (890.9 µg) versus FKS immunized, non-
infected mice (538.4 µg).
SP-A and SP-D bind to Coccidioidal antigens
We further examined the binding of SP-A and SP-D to
Coccidioidal antigens (CDN-lysate and CDN-filtrate)
coated onto microtiter wells (Fig 5). Both SP-A and SP-D
bound to coccidioidal antigens, but not to BSA in a con-
centration-dependent manner (Fig 5). Binding of SP-A to
CDN-lysate and CDN-filtrate antigens was saturable, and
maximum SP-A binding was reached between 2.5–5 µg/
ml and 5–10 µg/ml, respectively (Fig 5A). Similarly bind-
ing of SP-D to CDN-lysate and CDN-filtrate antigens was
also saturable, and maximum SP-D binding was reached
between 5–10 µg/ml (Fig 5B).
Discussion
In the present study we found that the levels of pulmonary
surfactant collectins were altered in the lungs of C. posa-
dasii infected mice, but were intact in lungs of C. posadasii
protected mice after immunization with protective FKS
vaccine. Furthermore, our results suggest that both SP-A
and SP-D bind to Coccidioidal antigens. This is the first
study where the amounts of SP-A and SP-D were meas-
ured in BALF samples from mice infected with lethal dose
of C. posadasii and the binding of pulmonary collectins to
Coccidioidal antigens was assessed. Since lung is the first
organ of the body that comes into contact with air-borne
C. posadasii arthroconidia, we hypothesized that the pul-
monary surfactant may play an important role in regulat-
ing the immune response against C. posadasii. Among four
surfactant proteins, SP-A and SP-D, interact with most of
the clinically important fungal pathogens including Pneu-
mocystis carinii [23]Cryptococcus neoformans [24], Aspergillus
fumigatus [25] and Candida albicans [26]. SP-D has been
shown to bind to C. albicans and directly inhibit growth
by aggregation of the organism without involvement of
macrophage dependent phagocytosis [27]. On the other
Fungal load in the lung and spleen tissues of C. posadasii  infected BALB/c mice (n = 5) Figure 4
Fungal load in the lung and spleen tissues of C. posadasii 
infected BALB/c mice (n = 5). The numbers of fungal colonies 
(CFU) were normalized with organ weight (g).
Binding of (A) SP-A and (B) SP-D to Coccidioidal antigens  (CDN-lysate and CDN-filtrate) Figure 5
Binding of (A) SP-A and (B) SP-D to Coccidioidal antigens 
(CDN-lysate and CDN-filtrate). The binding of 1–10 µg/ml 
purified human SP-A or recombinant SP-D proteins was 
detected in CDN-lysate or CDN-filtrate or BSA coated wells 
(0.5 µg/well). Results are from one representative experi-
ment of two independent experiments performed in dupli-
cate. Values are shown as mean+SEM. In some cases, the 
error bars are smaller than the symbols.Respiratory Research 2004, 5:28 http://respiratory-research.com/content/5/1/28
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hand, surfactant proteins also induce phagocytosis,
activation and killing of A. fumigatus conidia and C. neo-
formans by alveolar macrophages and neutrophils [28,29].
In support of these findings, further evidence comes from
a study by Madan et al., that suggests that the introduction
of recombinant SP-D improves the lung function and
increases the survival rate of mice infected with A.
fumigatus [25]. The decrease in amounts of SP-A and SP-D
during C. posadasii infection versus the unaltered amounts
in the lungs of protected mice and binding of collectins to
Coccidioidal antigens indicate that pulmonary collectins
may be involved in uptake/phagocytosis of C. posadasii by
antigen presenting cells and downstream immune
regulation.
Besides changes in amounts of SP-A and SP-D, a decrease
in the amount of BALF phospholipids was also observed
in C. posadasii infected mice (Table 2). Earlier, Sheehan et
al., [29] and Hoffman et al., [30] have reported similar
findings of reduced surfactant phospholipid level in BALF
samples of rats and humans infected with Pneumocystis
carinii [29,30]. To date, however, the information is lack-
ing concerning how surfactant phospholipids may be
involved in host defense [31]. Likewise, the mechanisms
underlying the decrease of BALF surfactant in murine
model of Coccidioidomycosis remain to be defined. We
speculate that the reduction in the collectins and phos-
pholipids could be either due to metabolic dysfunction of
pulmonary type II epithelial cells during C. posadasii infec-
tion or due to their utilization in the binding and uptake
of  C. posadasii by local antigen presenting cells. The
metabolic pathways of pulmonary type II epithelial cells
may be affected by secondary inflammatory mediators,
such as TNF-α or IL-1β, secreted by inflammatory cells
during C. posadasii infection. A variety of host inflamma-
tory mediators and substances such as, cytokines (TNF-α)
and growth factors are released during infection and
inflammation. These cytokines and growth factors affect
the synthesis and secretion of pulmonary surfactant by
pulmonary epithelial cells [32,33]. In the present study we
found slightly increased levels of SP-D in C. posadasii pro-
tected mice, but not of SP-A (Fig 2). We speculate that the
difference could be due to diverse mechanisms for regula-
tion of SP-A and SP-D expression. Probably the cytokines
and chemokines that are released as a result of FKS
vaccination (protective immune response) increase the
SP-D expression, but do not affect the SP-A expression. As
reported earlier, the expression of SP-A and SP-D is differ-
entially regulated during lung infection [34]. In future,
more studies are warranted to understand the mechanism
of the alterations in levels of surfactant phospholipids, SP-
A and SP-D.
At present, the treatment of C. posadasii infected patients
with disseminated disease is not very effective [35]. Treat-
ment with anti-fungal agents is most often related to
relapse of the infection and side effects on the body. Ear-
lier, the FKS based immunization has been found protec-
tive against Coccidioides  infection in murine model of
coccidioidomycosis, but failed in humans [35]. More pre-
clinical studies on developing different vaccine strategies
are underway. Since C. posadasii and C. immitis are highly
virulent organisms, cause endemic infection, and pose a
risk for bioterrorism, there is an urgent need for discovery
of improved therapeutic drugs and regimens or preventive
vaccines [3,35].
Conclusions
In future, clearance experiments after in vivo administra-
tion of artificial or natural surfactant in C. posadasii
infected mice may be useful in determining their thera-
peutic usefulness. We speculate that the findings from our
present study would initiate similar studies to understand
the role of pulmonary innate immune components in
infectious diseases caused by C. posadasii or other virulent
respiratory pathogens.
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